Metachromatic leukodystrophy: A single‐center longitudinal study of 45 patients
Open Access
- 15 April 2021
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (5) , 1151-1164
Abstract
In this study, we characterize the natural course of metachromatic leukodystrophy (MLD), explore intra/inter group differences, and identify biomarkers to monitor disease progression. This is a longitudinal observational study. Genotype and characteristics at disease onset were recorded. Time‐to‐event analyses were performed to assess time to major disease‐related milestones in different subgroups. Longitudinal trajectories of nerve conduction velocities (NCV), brain MRI score, and brainstem auditory evoked responses (BAERs) were described. We recruited 22 late‐infantile, 14 early‐juvenile, 5 late‐juvenile, and 4 adult MLD patients. Thirty‐four were prospectively evaluated (median FU time 43 months). In late‐infantile patients, the attainment of independent walking was associated with a later age at dysphagia. In early‐juvenile, the presence of isolated cognitive impairment at onset was not a favorable prognostic factor. Late‐infantile and early‐juvenile subjects showed similar rapid loss of ambulation and onset of seizures, but late‐infantile displayed earlier loss of trunk control, dysphagia, and death. We found significant differences in all major disease‐related milestones (except death) between early‐juvenile and late‐juvenile patients. Late‐juvenile and adult patients both presented with a predominant cognitive impairment, mild/no peripheral neuropathy, lower brain MRI score at plateau compared to LI/EJ, and later cerebellar involvement. NCV and BAER were consistently severely abnormal in late‐infantile but not in older subjects, in whom both NCV and BAER were variably affected, with no deterioration over time in some cases. This study clarifies intra/inter group differences between MLD subtypes and provides additional indications regarding reliable clinical and instrumental tools to monitor disease progression and to serve as areference to evaluate the efficacy of future therapeutic interventions inthe different MLD variants.Keywords
Funding Information
- GlaxoSmithKline
- Fondazione Telethon (Telethon Grant 2003‐2005/Clinical research project B "Clinical trial in Metachromatic Leukodystrophy" Communicating Editor: Carla E. Hollak)
This publication has 37 references indexed in Scilit:
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic LeukodystrophyScience, 2013
- The natural course of gross motor deterioration in metachromatic leukodystrophyDevelopmental Medicine & Child Neurology, 2011
- Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical courseJournal of Inherited Metabolic Disease, 2011
- Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophyJournal of Inherited Metabolic Disease, 2010
- Characterization of new arylsulfatase A gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophyHuman Mutation, 2009
- Molecular analysis ofARSAandPSAPgenes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novelARSAallelesHuman Mutation, 2008
- Molecular and phenotypic characteristics of metachromatic leukodystrophy patients from PolandClinical Genetics, 2005
- Brain-stem auditory and visual evoked potentials in children with Krabbe diseaseClinical Neurophysiology, 2004
- Biochemical characterization of two (C300F, P425T) arylsulfatase a missense mutationsAmerican Journal of Medical Genetics Part A, 2002
- Early motor development in metachromatic leucodystrophyArchives of Disease in Childhood, 1981